Cover Image
Market Research Report
Product code
997347

Market Spotlight: Acne

Published: | Datamonitor Healthcare | 46 Pages | Delivery time: 1-2 business days

Price

Back to Top
Market Spotlight: Acne
Published: March 15, 2021
Datamonitor Healthcare
Content info: 46 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2019, there were approximately 612.5 million prevalent cases of acne worldwide, and forecasts that number to increase to 658.6 million prevalent cases by 2028.

Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes.

The majority of industry-sponsored drugs in active clinical development for acne are in Phase II, with just a single product in the NDA/BLA stage.

Therapies in development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.

The only high-impact upcoming event for drugs in the acne space is an expected PDUFA date for Twyneo. The overall likelihood of approval of a Phase I dermatology-general asset is 20.2%, and the average probability a drug advances from Phase III is 68%. Drugs, on average, take 8.8 years from Phase I to approval in the dermatology-general space, as well as in the overall dermatology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for acne have been in the late phases of development, with 52% of trials in Phase III-IV, and 48% in Phase I-II.

The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.

GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for acne, followed by AbbVie.

Table of Contents
Product Code: DMKC0181187

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Topical therapy
  • Systemic therapy
  • Physical treatments

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • VB 1953 for Acne (June 16, 2020)
  • DMT310 for Acne (June 10, 2020)
  • FCD105 for Acne (June 2, 2020)
  • Twyneo for Acne (December 30, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Cassiopea's Winlevi Brings New Drug Class To Acne Market

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • GSK Inks Dermatology Pact With Eligo
  • L'Oreal's Microbiome Explorations Lead To Micreos Deal For Next-Gen Antibacterial
  • Paratek, Almirall Partner To Bring Acne Medicine To China

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of acne, 2019-28
  • Figure 2: Overview of pipeline drugs for acne in the US
  • Figure 3: Pipeline drugs for acne, by company
  • Figure 4: Pipeline drugs for acne, by drug type
  • Figure 5: Pipeline drugs for acne, by classification
  • Figure 6: VB 1953 for Acne (June 16, 2020): Phase II - Facial Acne Vulgaris
  • Figure 7: DMT310 for Acne (June 10, 2020): Phase IIb - 003
  • Figure 8: FCD105 for Acne (June 2, 2020): Phase II - Acne Vulgaris
  • Figure 9: Twyneo for Acne (December 30, 2019): Phase III - SGT-65-04, Phase III - SGT-65-05
  • Figure 10: Key upcoming events in acne
  • Figure 11: Probability of success in the dermatology-general pipeline
  • Figure 12: Clinical trials in acne
  • Figure 13: Top 10 drugs for clinical trials in acne
  • Figure 14: Top 10 companies for clinical trials in acne
  • Figure 15: Trial locations in acne
  • Figure 16: Acne trials status
  • Figure 17: Acne trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of acne, 2019-28
  • Table 2: Marketed drugs for acne
  • Table 3: Pipeline drugs for acne in the US
  • Table 4: VB 1953 for Acne (June 16, 2020)
  • Table 5: DMT310 for Acne (June 10, 2020)
  • Table 6: FCD105 for Acne (June 2, 2020)
  • Table 7: Twyneo for Acne (December 30, 2019)
  • Table 8: Historical global sales, by drug ($m), 2015-19
  • Table 9: Forecasted global sales, by drug ($m), 2021-25